Malaga

• Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended
  2023-503571-19-00 5 2022-01-20 Chronic Obstructive Pulmonary Disease (COPD)
• A Phase 1b, Open-Label, Dose-Escalation Trial of the Safety of and Antigen-Specific Immune Responses Elicited by VB.10 NEO in Combination Wi … Ended
  2023-509996-18-00 1 2022-01-18 Locally advanced and metastatic solid tumor including non-small cell l
• A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu … Ended
  2023-507189-17-00 4 2022-01-09 Muscle-Invasive Urothelial Carcinoma of the Bladder
• A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended
  2024-512052-38-00 9 2021-12-02 Advanced triple negative breast cancer
• MENACWY=MEN7B-003 Ended
  2023-506449-40-00 9 2021-11-29 Infections, Meningococcal
• Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe … Ended
  2022-500752-39-00 5 2021-11-25 Prevention of Respiratory syncytial virus (RSV) infection in infants a
• A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended
  2024-514934-19-00 5 2021-11-08 Post-surgical neuropathic pain
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma
• Evaluation of the efficacy and safety of topical treatment on clinical signs and symptoms of dry eye disease associated with moderate meibom … Ended
  2024-518093-13-00 6 2021-10-26 Dry Eye and Meibomian Gland Dysfunction
• SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS Ended
  2024-519633-35-00 6 2021-10-25 Resectable pancreatic adenocarcinoma with risk factors
• Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One … Ended
  2023-504715-33-00 5 2021-09-27 Psoriatic Arthritis
• A Drug Absorption Study of MK-3475A in Participants with Solid Tumors Ended
  2023-505340-19-00 3 2021-09-20 Advanced or Metastatic Solid Tumors
• Study to Evaluate the Safety and Efficacy of Treatment with NLM-001 before Standard Chemotherapy plus Zalifrelimab in Patients with Advanced … Ended
  2024-518852-22-00 3 2021-09-03 Advanced Pancreatic Cancer
• A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) Ended
  2023-508340-22-00 4 2021-08-11 metastatic or unresectable, recurrent HNSCC
• A Phase 2 study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma … Ended
  2023-508342-17-00 4 2021-08-11 metastatic or unresectable, recurrent HNSCC
• A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan … Ended
  2024-512227-36-00 9 2021-07-28 Advanced solid tumors
• A study of GSK3511294 (Depemokimab) in participants who were previously enrolled in 206713 or 213744; Open-Label Extension Ended
  2023-505203-23-01 5 2021-07-26 Severe asthma with an eosinophilic phenotype
• Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n … Ended
  2023-507431-37-00 5 2021-07-23 relapsing multiple sclerosis (RMS)
• Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR M … Ended
  2023-509776-41-00 3 2021-06-30 Non-small cell lung cancer (NSCLC)
• A trial to assess the long-term safety of octreotide subcutaneous depot in patients with acromegaly Ended
  2024-510667-33-00 5 2021-06-03 Acromegaly
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab … Ended
  2023-507317-10-00 5 2021-05-10 Locally advanced, unresectable, or metastatic non small cell lung canc
• Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended
  2023-507977-16-00 4 2021-05-10 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
• "A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended
  2023-505787-11-00 5 2021-04-29 Severe and inadequately controlled asthma

Showing 961–984 of 1,056 trials